Risk factors for fibrosis progression in non-alcoholic steatohepatitis: Analysis of the European cohort in the real-world GAIN study

[EN] Objective: To better understand drivers of disease progression in non-alcoholic steatohepatitis (NASH), we assessed clinical and sociodemographic markers of fibrosis progression in adults with NASH. Patients and methods: Physician-reported patient demographics and clinical characteristics were...

Descripción completa

Detalles Bibliográficos
Autores: Shaikh, Anum, Pedra, Gabriel, Ruiz-Casas, Leonardo, Franks, Bethany, Dhillon, Harpal, Fernandes, João Diogo da Rocha, Mangla, Kamal Kant, Augusto, Margarida, Romero-Gómez, Manuel, Schattenberg, Jörn M.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/370616
Acceso en línea:http://hdl.handle.net/10261/370616
https://api.elsevier.com/content/abstract/scopus_id/85177176517
Access Level:acceso abierto
Palabra clave:Risk factor
Advanced fibrosis
Biopsia hepática
Enfermedad del hígado graso sin alcohol
Esteatohepatitis no alcohólica
Factor de riesgo
Fibrosis avanzada
Liver biopsy
Non-alcoholic fatty liver disease
Non-alcoholic steatohepatitis
id ES_f8b2eb18f47c19a310ad631f2acca82b
oai_identifier_str oai:digital.csic.es:10261/370616
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Risk factors for fibrosis progression in non-alcoholic steatohepatitis: Analysis of the European cohort in the real-world GAIN study
Factores de riesgo para la progresión de la fibrosis en la esteatohepatitis no alcohólica: análisis de la cohorte europea en el estudio GAIN del mundo real
title Risk factors for fibrosis progression in non-alcoholic steatohepatitis: Analysis of the European cohort in the real-world GAIN study
spellingShingle Risk factors for fibrosis progression in non-alcoholic steatohepatitis: Analysis of the European cohort in the real-world GAIN study
Shaikh, Anum
Risk factor
Advanced fibrosis
Biopsia hepática
Enfermedad del hígado graso sin alcohol
Esteatohepatitis no alcohólica
Factor de riesgo
Fibrosis avanzada
Liver biopsy
Non-alcoholic fatty liver disease
Non-alcoholic steatohepatitis
title_short Risk factors for fibrosis progression in non-alcoholic steatohepatitis: Analysis of the European cohort in the real-world GAIN study
title_full Risk factors for fibrosis progression in non-alcoholic steatohepatitis: Analysis of the European cohort in the real-world GAIN study
title_fullStr Risk factors for fibrosis progression in non-alcoholic steatohepatitis: Analysis of the European cohort in the real-world GAIN study
title_full_unstemmed Risk factors for fibrosis progression in non-alcoholic steatohepatitis: Analysis of the European cohort in the real-world GAIN study
title_sort Risk factors for fibrosis progression in non-alcoholic steatohepatitis: Analysis of the European cohort in the real-world GAIN study
dc.creator.none.fl_str_mv Shaikh, Anum
Pedra, Gabriel
Ruiz-Casas, Leonardo
Franks, Bethany
Dhillon, Harpal
Fernandes, João Diogo da Rocha
Mangla, Kamal Kant
Augusto, Margarida
Romero-Gómez, Manuel
Schattenberg, Jörn M.
author Shaikh, Anum
author_facet Shaikh, Anum
Pedra, Gabriel
Ruiz-Casas, Leonardo
Franks, Bethany
Dhillon, Harpal
Fernandes, João Diogo da Rocha
Mangla, Kamal Kant
Augusto, Margarida
Romero-Gómez, Manuel
Schattenberg, Jörn M.
author_role author
author2 Pedra, Gabriel
Ruiz-Casas, Leonardo
Franks, Bethany
Dhillon, Harpal
Fernandes, João Diogo da Rocha
Mangla, Kamal Kant
Augusto, Margarida
Romero-Gómez, Manuel
Schattenberg, Jörn M.
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Novo Nordisk
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Risk factor
Advanced fibrosis
Biopsia hepática
Enfermedad del hígado graso sin alcohol
Esteatohepatitis no alcohólica
Factor de riesgo
Fibrosis avanzada
Liver biopsy
Non-alcoholic fatty liver disease
Non-alcoholic steatohepatitis
topic Risk factor
Advanced fibrosis
Biopsia hepática
Enfermedad del hígado graso sin alcohol
Esteatohepatitis no alcohólica
Factor de riesgo
Fibrosis avanzada
Liver biopsy
Non-alcoholic fatty liver disease
Non-alcoholic steatohepatitis
description [EN] Objective: To better understand drivers of disease progression in non-alcoholic steatohepatitis (NASH), we assessed clinical and sociodemographic markers of fibrosis progression in adults with NASH. Patients and methods: Physician-reported patient demographics and clinical characteristics were utilised from the real-world Global Assessment of the Impact of NASH (GAIN) study. Factors associated with likelihood of fibrosis progression since NASH diagnosis were identified using a logistic regression model. Results: Overall, 2349 patients in Europe from the GAIN study were included; mean age was 54.6 years and 41% were women. Significant covariates included age, years since diagnosis, employment status, fibrosis stage at diagnosis, type 2 diabetes mellitus, hypertension, liver transplant and liver biopsy at diagnosis. Risk of progression was 1.16 (95% confidence interval 1.12–1.20; p < 0.001) times higher for each additional year since NASH diagnosis and 5.43 (2.68–11.37; p < 0.001) times higher when physicians proposed a liver transplant at diagnosis. Compared with full-time employed patients, risk of progression was 1.77 (1.19–2.60; p = 0.004) times higher for unemployed patients and 3.16 (1.30–7.63; p = 0.010) times higher for those unable to work due to NASH. Conclusions: Disease duration, NASH severity and presence of other metabolic comorbidities could help to assess risk of progression in patients with NASH.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/370616
https://api.elsevier.com/content/abstract/scopus_id/85177176517
url http://hdl.handle.net/10261/370616
https://api.elsevier.com/content/abstract/scopus_id/85177176517
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv The underlying dataset has been published as supplementary material of the article in the publisher platform at DOI https://doi.org/10.1016/j.gastrohep.2023.10.005
https://doi.org/10.1016/j.gastrohep.2023.10.005
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425025670447104
spelling Risk factors for fibrosis progression in non-alcoholic steatohepatitis: Analysis of the European cohort in the real-world GAIN studyFactores de riesgo para la progresión de la fibrosis en la esteatohepatitis no alcohólica: análisis de la cohorte europea en el estudio GAIN del mundo realShaikh, AnumPedra, GabrielRuiz-Casas, LeonardoFranks, BethanyDhillon, HarpalFernandes, João Diogo da RochaMangla, Kamal KantAugusto, MargaridaRomero-Gómez, ManuelSchattenberg, Jörn M.Risk factorAdvanced fibrosisBiopsia hepáticaEnfermedad del hígado graso sin alcoholEsteatohepatitis no alcohólicaFactor de riesgoFibrosis avanzadaLiver biopsyNon-alcoholic fatty liver diseaseNon-alcoholic steatohepatitis[EN] Objective: To better understand drivers of disease progression in non-alcoholic steatohepatitis (NASH), we assessed clinical and sociodemographic markers of fibrosis progression in adults with NASH. Patients and methods: Physician-reported patient demographics and clinical characteristics were utilised from the real-world Global Assessment of the Impact of NASH (GAIN) study. Factors associated with likelihood of fibrosis progression since NASH diagnosis were identified using a logistic regression model. Results: Overall, 2349 patients in Europe from the GAIN study were included; mean age was 54.6 years and 41% were women. Significant covariates included age, years since diagnosis, employment status, fibrosis stage at diagnosis, type 2 diabetes mellitus, hypertension, liver transplant and liver biopsy at diagnosis. Risk of progression was 1.16 (95% confidence interval 1.12–1.20; p < 0.001) times higher for each additional year since NASH diagnosis and 5.43 (2.68–11.37; p < 0.001) times higher when physicians proposed a liver transplant at diagnosis. Compared with full-time employed patients, risk of progression was 1.77 (1.19–2.60; p = 0.004) times higher for unemployed patients and 3.16 (1.30–7.63; p = 0.010) times higher for those unable to work due to NASH. Conclusions: Disease duration, NASH severity and presence of other metabolic comorbidities could help to assess risk of progression in patients with NASH.[ES] Objetivo: Para comprender mejor los factores que impulsan la progresión de la enfermedad en la esteatohepatitis no alcohólica (NASH), evaluamos los marcadores clínicos y sociodemográficos de la progresión de la fibrosis en adultos con NASH. Pacientes y métodos: Se utilizaron las características demográficas y clínicas de los pacientes informadas por los médicos del estudio de Evaluación Global del Impacto de NASH (GAIN) del mundo real. Los factores asociados con la probabilidad de progresión de la fibrosis desde el diagnóstico de EHNA se identificaron mediante un modelo de regresión logística. Resultados: En total, se incluyeron 2.349 pacientes en Europa del estudio GAIN; la edad media fue 54,6 años y el 41% eran mujeres. Las covariables significativas incluyeron edad, años desde el diagnóstico, situación laboral, estadio de fibrosis en el momento del diagnóstico, diabetes mellitus tipo 2, hipertensión, trasplante de hígado y biopsia de hígado en el momento del diagnóstico. El riesgo de progresión fue 1,16 (intervalo de confianza del 95% 1,12-1,20; p < 0,001) veces mayor por cada año adicional desde el diagnóstico de EHNA y 5,43 (2,68-11,37; p < 0,001) veces mayor cuando los médicos propusieron un trasplante de hígado. en el momento del diagnóstico. En comparación con los pacientes empleados a tiempo completo, el riesgo de progresión fue 1,77 (1,19-2,60; p = 0,004) veces mayor para los pacientes desempleados y 3,16 (1,30-7,63; p = 0,010) veces mayor para aquellos que no podían trabajar debido a a NASH. Conclusiones: La duración de la enfermedad, la gravedad de NASH y la presencia de otras comorbilidades metabólicas podrían ayudar a evaluar el riesgo de progresión en pacientes con NASH.This study was sponsored by Novo Nordisk A/S.Peer reviewedElsevierNovo NordiskConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202420242024info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/370616https://api.elsevier.com/content/abstract/scopus_id/85177176517reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)InglésThe underlying dataset has been published as supplementary material of the article in the publisher platform at DOI https://doi.org/10.1016/j.gastrohep.2023.10.005https://doi.org/10.1016/j.gastrohep.2023.10.005Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3706162026-05-22T06:33:51Z
score 15,81155

Similares en LA Referencia